CIK 0001770069 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MapLight Therapeutics, Inc.
Sign in to watch- Ticker
- MPLT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832163243
- Phone
- 650-839-4360
- Business address
- 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
- Former names
- Alvarado Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,256,232
- in 7 filings, $193K under 10b5-1 plans
Net −$1,256,232. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Kroeger Christopher A. −$595K Chief Executive Officer sold 6% of stake
- Hanson Kristopher −$266K General Counsel sold 17% of stake
- Foff Erin Pennock −$124K Chief Medical Officer sold 5% of stake
- Kreitzer Anatol −$96K Chief Discovery Officer sold 7% of stake
- Lillie James Woodruff −$93K Chief Scientific Officer sold 5% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | Kroeger Christopher A. Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +93,955 | 93,955 | ||
| 2026-08-14 | Catalyst4, Inc. 10% owner | Purchase | +4,400,000 | $11.38 | $50.1M | 25,306,689 |
| 2026-08-14 | Catalyst4, Inc. 10% owner | Purchase · Warrants (right to buy) | +2,928,686 | $11.38 | $33.3M | 2,928,686 |
| 2026-08-03 | Lillie James Woodruff Chief Scientific Officer | Sale 10b5-1 | −22,082 | $12.54 | $277K | 202,380 |
| 2026-07-30 | Catalyst4, Inc. 10% owner | Purchase | +1,000,000 | $13.00 | $13.0M | 20,906,689 |
| 2026-07-29 | Catalyst4, Inc. 10% owner | Purchase | +3,000 | $12.63 | $38K | 19,906,689 |
| 2026-07-28 | Catalyst4, Inc. 10% owner | Purchase | +141,088 | $10.74 | $1.5M | 19,838,552 |
| 2026-07-28 | Catalyst4, Inc. 10% owner | Purchase | +65,137 | $11.69 | $761K | 19,903,689 |
| 2026-07-28 | Cox Troy Director | Purchase | +15,620 | $9.52 | $149K | 15,620 |
| 2026-07-17 | Kreitzer Anatol Chief Discovery Officer | Sale 10b5-1 | −2,833 | $37.05 | $105K | 189,246 |
| 2026-07-17 | Kreitzer Anatol Chief Discovery Officer | Sale 10b5-1 | −14,140 | $37.70 | $533K | 175,106 |
| 2026-07-17 | Kreitzer Anatol Chief Discovery Officer | Sale 10b5-1 | −200 | $38.39 | $8K | 174,906 |
| 2026-07-17 | GILLIS JONATHAN CAO and Interim CFO | Sale 10b5-1 | −600 | $36.51 | $22K | 162,109 |
| 2026-07-17 | GILLIS JONATHAN CAO and Interim CFO | Sale 10b5-1 | −16,969 | $37.61 | $638K | 145,140 |
| 2026-07-17 | GILLIS JONATHAN CAO and Interim CFO | Sale 10b5-1 | −900 | $38.17 | $34K | 144,240 |
| 2026-07-17 | Foff Erin Pennock Chief Medical Officer | Sale 10b5-1 | −3,656 | $37.90 | $139K | 298,901 |
| 2026-07-17 | Hanson Kristopher General Counsel | Sale | −1,130 | $37.90 | $43K | 145,823 |
| 2026-07-17 | Lillie James Woodruff Chief Scientific Officer | Sale | −2,077 | $37.90 | $79K | 224,462 |
| 2026-07-17 | Kroeger Christopher A. Chief Executive Officer | Sale | −16,779 | $37.90 | $636K | 1,246,455 |
| 2026-07-16 | Kreitzer Anatol Chief Discovery Officer | Sale 10b5-1 | −7,464 | $36.66 | $274K | 193,671 |
Page 2 of 12 · 239 trades